Curis vs Eloxx Pharmaceuticals
CRIS and ELOX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CRIS and ELOX compare
Eloxx Pharmaceuticals is the larger company, worth 57 times as much as Curis ($53.1M against $930K).
Eloxx Pharmaceuticals scores higher on the StockData Score (7 against 5 for Curis), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CRIS | ELOX |
|---|---|---|
| Size and price | ||
| Market cap | $930K | $53.1M |
| Share price | $0.445 | $13.15 |
| Change, 1 year | −98.2% | 1195350% |
| Change, 5 years | −100.0% | −97.8% |
| Beta (5Y) | 1.90 | – |
| Employees | 24 | 7 |
| StockData Score | ||
| Total score | 5 | 7 (better) |
| Valuation score | 1 | 1 |
| Growth score | 0 | 0 |
| Performance score | 0 | 1 (better) |
| Health score | 4 | 5 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | 0.4× (better) | 1.1× |
| Growth | ||
| Revenue growth (TTM) | – | −100% |
| Revenue growth, 5Y average | −2.7% | – |
| Profitability | ||
| Return on equity | – | −54.3% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 0.43 | 3.74 (better) |
| Altman Z-score | −98.36 | −4.40 (better) |
| Piotroski F-score | 3 | 3 |
| Dividends and buybacks | ||
| Buyback yield | – | 0.00% |
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 32.1% | 71.8% |
| Held by insiders | 20.4% | 42.6% |
| Insider net buying, 12 months | $5.5K | – |
| Short interest, % of float | 61.8% | 2.3% |
Go deeper
- CRIS stock overview
- CRIS income statement
- CRIS valuation and score
- ELOX stock overview
- ELOX income statement
- ELOX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.